Eli Lilly Retained Earnings (Accumulated Deficit) 2010-2024 | LLY

Eli Lilly retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
  • Eli Lilly retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $13.627B, a 32.18% increase year-over-year.
  • Eli Lilly retained earnings (accumulated deficit) for 2023 were $10.312B, a 2.69% increase from 2022.
  • Eli Lilly retained earnings (accumulated deficit) for 2022 were $10.043B, a 12.1% increase from 2021.
  • Eli Lilly retained earnings (accumulated deficit) for 2021 were $8.959B, a 14.41% increase from 2020.
Eli Lilly Annual Retained Earnings (Accumulated Deficit)
(Millions of US $)
2023 $10,312
2022 $10,043
2021 $8,959
2020 $7,830
2019 $4,920
2018 $11,396
2017 $13,894
2016 $16,046
2015 $16,012
2014 $16,483
2013 $16,992
2012 $16,088
2011 $14,898
2010 $12,733
2009 $9,830
Eli Lilly Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $)
2024-09-30 $13,627
2024-06-30 $13,178
2024-03-31 $12,554
2023-12-31 $10,312
2023-09-30 $10,310
2023-06-30 $10,369
2023-03-31 $10,639
2022-12-31 $10,043
2022-09-30 $10,007
2022-06-30 $8,556
2022-03-31 $9,369
2021-12-31 $8,959
2021-09-30 $9,639
2021-06-30 $8,530
2021-03-31 $9,181
2020-12-31 $7,830
2020-09-30 $7,154
2020-06-30 $6,617
2020-03-31 $5,879
2019-12-31 $4,920
2019-09-30 $4,982
2019-06-30 $4,318
2019-03-31 $4,879
2018-12-31 $11,396
2018-09-30 $14,409
2018-06-30 $14,247
2018-03-31 $16,608
2017-12-31 $13,894
2017-09-30 $16,146
2017-06-30 $15,590
2017-03-31 $15,877
2016-12-31 $16,046
2016-09-30 $16,602
2016-06-30 $15,824
2016-03-31 $16,155
2015-12-31 $16,012
2015-09-30 $16,857
2015-06-30 $16,115
2015-03-31 $16,707
2014-12-31 $16,483
2014-09-30 $17,407
2014-06-30 $17,204
2014-03-31 $17,665
2013-12-31 $16,992
2013-09-30 $17,811
2013-06-30 $16,609
2013-03-31 $16,462
2012-12-31 $16,088
2012-09-30 $17,062
2012-06-30 $15,736
2012-03-31 $15,907
2011-12-31 $14,898
2011-09-30 $15,126
2011-06-30 $13,888
2011-03-31 $13,785
2010-12-31 $12,733
2010-09-30 $12,647
2010-06-30 $11,344
2010-03-31 $11,077
2009-12-31 $9,830
2009-09-30 $9,993
2009-06-30 $9,050
2009-03-31 $8,968
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $692.744B $34.124B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
Stock Name Country Market Cap PE Ratio
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03
Innoviva (INVA) United States $1.195B 9.94